Liposomal Nanomaterials: A Rising Star in Glioma Treatment

2Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Glioma is a primary malignant tumor in the central nervous system. In recent years, the treatment of glioma has developed rapidly, but the overall survival of glioma patients has not significantly improved. Due to the presence of the blood–brain barrier and intracranial tumor barrier, many drugs with good effects to cure glioma in vitro cannot be accurately transported to the corresponding lesions. In order to enable anti-tumor drugs to overcome the barriers and target glioma, nanodrug delivery systems have emerged recently. It is gratifying that liposomes, as a multifunctional nanodrug delivery carrier, which can be compatible with hydrophilic and hydrophobic drugs, easily functionalized by various targeted ligands, biodegradable, and hypoimmunogenic in vivo, has become a quality choice to solve the intractable problem of glioma medication. Therefore, we focused on the liposome nanodrug delivery system, and summarized its current research progress in glioma. Hopefully, this review may provide new ideas for the research and development of liposome-based nanomaterials for the clinical treatment of glioma.

Cite

CITATION STYLE

APA

Gan, Y., Yu, Y., Xu, H., & Piao, H. (2024). Liposomal Nanomaterials: A Rising Star in Glioma Treatment. International Journal of Nanomedicine. Dove Medical Press Ltd. https://doi.org/10.2147/IJN.S470478

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free